SCHEMBL24784603

SCHEMBL24784603

COc1cc(F)cc(-c2ncc(CBr)cn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.40
▸ CYP1A1 P04798 3/20 0.36
▸ CYP1B1 Q16678 3/20 0.36
▸ LRRK2 Q5S007 3/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2E1 P05181 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C8 P10632 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2A6 P11509 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP4B1 P13584 1/20 0.36
▸ CYP2B6 P20813 1/20 0.36
▸ CYP3A5 P20815 1/20 0.36
▸ CYP2A7 P20853 1/20 0.36
▸ CYP3A7 P24462 1/20 0.36
▸ CYP2F1 P24903 1/20 0.36
▸ CYP2C18 P33260 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ CYP2J2 P51589 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103072 1.00 KDM1A (0.40) KDM1ACYP1A1CYP1B1LRRK2CYP1A2
SCHEMBL24784608 0.85 KDM1A (0.40) KDM1ACYP1A1CYP1B1LRRK2CYP1A2
SCHEMBL30103025 0.77 CLK4 (0.63) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL24785078 0.77 CLK4 (0.63) CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL25365883 0.76 ABL1 (0.44) KDM1ACYP1A1CYP1B1CYP1A2CYP2E1
SCHEMBL30103056 0.76 CLK4 (0.56) CLK4
SCHEMBL1662528 0.75 CYP4F2 (0.41) CYP4F2CYP4A11ALKBH1GRIN1GRIN2B
SCHEMBL29359230 0.75 CYP4F2 (0.41) CYP4F2CYP4A11ALKBH1GRIN1GRIN2B
SCHEMBL30103016 0.74 CYP1A2 (0.52) KDM1ACYP1A1CYP1B1LRRK2CYP1A2
SCHEMBL24785077 0.72 KDM1A (0.42) KDM1AGRK6ALKBH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022257960-A1 BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES 武汉人福创新药物研发中心有限公司 2022-12-15 — — WO disclosed
WO-2022257960-A1 BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES 武汉人福创新药物研发中心有限公司 2022-12-15 — — WO disclosed
Send feedback